Slides
Page 1
Sigma Healthcare Limited Annual General Meeting 21 October 2026
Page 2
Sigma Healthcare Limited 2026 Annual General Meeting Michael Sammells Chairman of Sigma 2
Page 3
Sigma Healthcare Limited Agenda 1. Chairman and CEO addresses 2. Financial Statements and Reports 3. Remuneration Report 4. Re-election of Directors 5. Remuneration arrangements for key executives 2026 Annual General Meeting Sigma is a healthcare business with significant scale, capability and market reach, offering defensive earnings characteristics and multiple pathways for long-term growth Proudly powering pharmacy 3
Page 4
Sigma Healthcare Limited Board of Directors 2026 Annual General Meeting Michael Sammells Chairman, Non-Executive Director, Chair of the Related Party Independent Board Committee Vikesh Ramsunder Managing Director and CEO Dr Christopher (Chris) Roberts AO Non-Executive Director, Chair of the Risk, Compliance and Sustainability Committee Annette Carey Non-Executive Director, Chair of the Nomination and Remuneration Committee Neville Mitchell Non-Executive Director, Chair of the Audit Committee Jack Gance Non-Executive Director Mario Verrocchi Executive Director, CEO – Retail Danielle Di Pilla Executive Director, Chief People Officer Damien Gance Non-Executive Director 4
Page 5
Sigma Healthcare Limited 2026 Annual General Meeting Strong first full-year performance as a merged group Earnings grew faster than revenue as scale improves efficiency $10.8bn Revenue +15.5% $1.09bn Normalised EBIT +20.6% $605m FY24 pro-forma EBIT FY24 to FY26 EBIT shows the strategic logic of the merger • Balance-sheet discipline: $663m net debt, equivalent to 0.57× normalised EBITDA. • Shareholder returns: Total FY26 dividend of 4.0 cents per share, fully franked. FY26 growth 15.5% 20.6% 22.3% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% Revenue Normalised EBIT NPAT 5
Page 6
Sigma Healthcare Limited 2026 Annual General Meeting Disciplined growth to build shareholder value 01 Australia Expand the network and grow like-for-like sales. Strengthen our network through a three-brand strategy - Chemist Warehouse, Amcal and DDS. 02 International Enter selected markets with discipline. Target attractive long- term returns. Measured UK entry through the Greenlight joint venture from FY27 03 Brands and products Differentiate our brands. Selectively grow own and exclusive labels. 04 Operating leverage Capture integration and synergy benefits. Improve supply-chain capacity and efficiency. Investment decisions require a clear strategic rationale and an appropriate return on capital 6
Page 7
Sigma Healthcare Limited 2026 Annual General Meeting Related-party protocols Independent oversight Ensure consistent and fair arrangements Protecting the interests of all shareholders Dedicated Independent Board Committee (IBC) supported by Working Group IBC approval for departures from standard templates or commercial terms, regardless of size Standard franchise agreements. No preferential founder agreements. Independent valuations Independent valuations support related- party property leases. 7
Page 8
Sigma Healthcare Limited 2026 Annual General Meeting ESG progress and community investment For sustainability strategy and climate-related risks and opportunities 82% More than $7.5m Measures form part of executive performance assessment Community investment Australia and New Zealand Waste diverted from landfill at Australian distribution centres 5,570 tonnes diverted from landfill Board accountability Health and safety 8
Page 9
Sigma Healthcare Limited Looking ahead
Page 10
Sigma Healthcare Limited 2026 Annual General Meeting Vikesh Ramsunder Managing Director and CEO 10
Page 11
Sigma Healthcare Limited 2026 Annual General Meeting Growing our network and lifting productivity Australian growth 15.9% 24 new stores 18 refurbishments 561 CW stores at 30 June International expansion 23.3% 20 new stores Ireland profitable Preparing for UK launch Supply-chain productivity 579m+ 35m more units than last year Greater scale and automation support operating leverage CW branded store sales growth CW branded store sales growth Units delivered in Australia 11
Page 12
Sigma Healthcare Limited 2026 Annual General Meeting Delivered progress Preston support centres consolidated. E-commerce DC in Preston closed Western Australia volume and South Australia volume transferred to Sigma’s legacy DC in WA and SA Next phase Chemist Warehouse integration into Sigma’s SAP platform Fewer technology applications FY29 synergies target Full realisation anticipated during FY29 Synergy delivery in line with expectations $32.6m Synergies realised $25.9m one-off integration costs Store systems are outside the technology integration scope $100m Per annum synergies 12
Page 13
Sigma Healthcare Limited Chemist Warehouse trading update 2026 Annual General Meeting Chemist Warehouse Palmerston North, New Zealand Australian CW branded store network* 14 Stores expected to join the network in 1H27 42 Chemist Warehouse -Australia 19 Amcal and Discount Drug Stores - Australia International stores 13 International CW store network# 12.1% sales 9.8% LFL sales 30.2% sales 15.8% LFL sales * Financial year to date to 16 October 2026 # First quarter of FY27 (to 30 September 2026). International sales reflects constant currency.
Page 14
Sigma Healthcare Limited Thank you Thank you For more information contact: Gary Woodford Head of Corporate Affairs and Investor Relations gary.woodford@sigmahealthcare.com.au www.sigmahealthcare.com.au
Page 15
Sigma Healthcare Limited Important Notice 2026 Annual General Meeting The information contained in this presentation about Sigma Healthcare Limited and its subsidiaries (Sigma) is designed to provide: • an overview of the financial and operational highlights for Sigma for the full year period ending 30 June 2026; and • a high-level overview of aspects of the operations of Sigma, including comments about Sigma’s expectations of the outlook for FY27 and future years, as at 21 October 2026. This presentation contains forward-looking statements relating to operations of Sigma that are based on management’s current expectations, estimates and projections about matters relevant to Sigma’s future financial performance. Any forward-looking statements, assumptions, projections, estimates and outcomes contained in this presentation should not be relied upon as a representation or warranty, express or implied by Sigma. They are not an assurance or guarantee of future performance nor should be taken to be, and involve known and unknown risks, uncertainties and other factors which are beyond the control of Sigma in relation to the future business performance or results of Sigma or the likelihood that the assumptions, estimates or outcomes will be achieved. While Sigma, its officers and management have made every effort to ensure the accuracy of the information in this presentation, this presentation is provided for information only. Neither Sigma, its directors, officers, agents, employees or advisors make any representation, or given any warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information, forward-looking statements, opinions, estimates, projections, outcomes and conclusions contained in this presentation. Accordingly, to the maximum extent permitted by law, Sigma, its directors, officers, agents, employees and advisors exclude and disclaim any liability, whether direct or indirect, in respect of the accuracy or completeness of the information or any other opinions contained in this presentation or errors, omissions, statements or for any loss, howsoever arising, from anything done in reliance or the use of this presentation. Sigma assumes no obligation to update or revise any forward-looking statements. Nothing in this presentation constitutes investment advice and this presentation shall not constitute an offer, invitation, solicitation or other recommendation to sell or buy any securities or otherwise engage in any investment activity in Sigma Healthcare Limited. Investors should make their own enquiries and seek their own professional advice (including financial and legal advice) before dealing in securities of Sigma Healthcare Limited. Due to rounding, numbers presented throughout this presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. 15